Cowen and Company’s Guardant Health GH Stock Holding History

Cowen and Company’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,800	Closed	-$109K	–	622
2022 Q4	$109K	Buy	+4,800	New	+$220K	0.01%	205

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Cowen and Company's GH Position: Q4 2024 in Review

Cowen and Company sold out of Guardant Health (GH) in Q4 2024, closing a stake of 2,000 shares — an estimated $45.9K sold.

Cowen and Company first reported a position in GH in Q3 2022 and held it in 3 quarters. The position peaked at $513K in Q3 2022. 297 funds tracked by Wall St. Rank hold GH as of Q4 2024.

Cowen and Company reported no remaining Guardant Health position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 2,000 Guardant Health shares in Q4 2024, an estimated $45.9K.
Cowen and Company first reported a position in Guardant Health in Q3 2022 and held it in 3 quarters.
Cowen and Company's Guardant Health position peaked at $513K in Q3 2022.
297 funds tracked by Wall St. Rank held Guardant Health as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.